{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antigènes CD11c : Questions médicales les plus fréquentes",
"headline": "Antigènes CD11c : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antigènes CD11c : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-26",
"dateModified": "2025-02-20",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antigènes CD11c"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Intégrine alphaX bêta2",
"url": "https://questionsmedicales.fr/mesh/D016167",
"about": {
"@type": "MedicalCondition",
"name": "Intégrine alphaX bêta2",
"code": {
"@type": "MedicalCode",
"code": "D016167",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.050.301.350.275"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Antigènes CD11c",
"alternateName": "CD11c Antigen",
"code": {
"@type": "MedicalCode",
"code": "D039521",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Lifei Hou",
"url": "https://questionsmedicales.fr/author/Lifei%20Hou",
"affiliation": {
"@type": "Organization",
"name": "Cardiac Anesthesia Division, Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA."
}
},
{
"@type": "Person",
"name": "Koichi Yuki",
"url": "https://questionsmedicales.fr/author/Koichi%20Yuki",
"affiliation": {
"@type": "Organization",
"name": "Cardiac Anesthesia Division, Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA."
}
},
{
"@type": "Person",
"name": "Wakiro Sato",
"url": "https://questionsmedicales.fr/author/Wakiro%20Sato",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Immunology (E.A., W.S., A.K., T. Yamamura), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo; Department of Neurology and Neurological Sciences (E.A., T. Yokota), Tokyo Medical and Dental University, Bunkyo; Department of Radiology (Y.K., N.S.); and Department of Neurology (Y.L., T.O.), National Center Hospital, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Youwei Lin",
"url": "https://questionsmedicales.fr/author/Youwei%20Lin",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Immunology (E.A., W.S., A.K., T. Yamamura), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo; Department of Neurology and Neurological Sciences (E.A., T. Yokota), Tokyo Medical and Dental University, Bunkyo; Department of Radiology (Y.K., N.S.); and Department of Neurology (Y.L., T.O.), National Center Hospital, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Tomoko Okamoto",
"url": "https://questionsmedicales.fr/author/Tomoko%20Okamoto",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Immunology (E.A., W.S., A.K., T. Yamamura), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo; Department of Neurology and Neurological Sciences (E.A., T. Yokota), Tokyo Medical and Dental University, Bunkyo; Department of Radiology (Y.K., N.S.); and Department of Neurology (Y.L., T.O.), National Center Hospital, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Predictive Value of Jugulo-omohyoid Lymph Nodes in Lateral Lymph Node Metastasis of Papillary Thyroid Cancer.",
"datePublished": "2024-05-21",
"url": "https://questionsmedicales.fr/article/38773428",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12902-024-01576-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Radiation, Lymph Node Dissection, or Both: Management of Lymph Node Micrometastases from Merkel Cell Carcinoma.",
"datePublished": "2023-04-27",
"url": "https://questionsmedicales.fr/article/37106277",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1245/s10434-023-13437-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Clinical outcomes of neoadjuvant therapy followed by selective inguinal lymph node dissection and total mesorectal excision for metastasized low rectal cancer.",
"datePublished": "2022-12-28",
"url": "https://questionsmedicales.fr/article/36577899",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00423-022-02739-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Robotic versus laparoscopic total mesorectal excision with lateral lymph node dissection for advanced rectal cancer: A systematic review and meta-analysis.",
"datePublished": "2024-05-29",
"url": "https://questionsmedicales.fr/article/38809911",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0304031"
}
},
{
"@type": "ScholarlyArticle",
"name": "Inguinal Lymph-Node Ratio (LNR) as a predictor of Pelvic Lymph-Node Metastasis in squamous cell carcinoma of penis.",
"datePublished": "2023-06-08",
"url": "https://questionsmedicales.fr/article/37315351",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.suronc.2023.101964"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Antigènes",
"item": "https://questionsmedicales.fr/mesh/D000941"
},
{
"@type": "ListItem",
"position": 4,
"name": "Antigènes de surface",
"item": "https://questionsmedicales.fr/mesh/D000954"
},
{
"@type": "ListItem",
"position": 5,
"name": "Molécules d'adhérence cellulaire",
"item": "https://questionsmedicales.fr/mesh/D015815"
},
{
"@type": "ListItem",
"position": 6,
"name": "Intégrine alphaX bêta2",
"item": "https://questionsmedicales.fr/mesh/D016167"
},
{
"@type": "ListItem",
"position": 7,
"name": "Antigènes CD11c",
"item": "https://questionsmedicales.fr/mesh/D039521"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antigènes CD11c - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antigènes CD11c",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antigènes CD11c",
"description": "Comment diagnostiquer une expression anormale de CD11c ?\nQuels tests sont utilisés pour détecter les antigènes CD11c ?\nLes antigènes CD11c sont-ils spécifiques à certaines maladies ?\nQuelle est l'importance des antigènes CD11c dans le diagnostic ?\nPeut-on mesurer les niveaux de CD11c dans le sang ?",
"url": "https://questionsmedicales.fr/mesh/D039521?mesh_terms=Lymph+Node+Excision&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antigènes CD11c",
"description": "Quels symptômes sont associés à une surexpression de CD11c ?\nLa présence de CD11c est-elle liée à des symptômes spécifiques ?\nLes antigènes CD11c sont-ils liés à des symptômes neurologiques ?\nComment les symptômes varient-ils selon les niveaux de CD11c ?\nLes symptômes d'une maladie liée à CD11c sont-ils réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D039521?mesh_terms=Lymph+Node+Excision&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antigènes CD11c",
"description": "Peut-on prévenir les maladies liées à CD11c ?\nY a-t-il des vaccins liés aux antigènes CD11c ?\nComment le dépistage précoce aide-t-il à prévenir les complications ?\nLes habitudes alimentaires influencent-elles CD11c ?\nLe stress a-t-il un impact sur CD11c ?",
"url": "https://questionsmedicales.fr/mesh/D039521?mesh_terms=Lymph+Node+Excision&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antigènes CD11c",
"description": "Quels traitements ciblent les antigènes CD11c ?\nLes traitements sont-ils efficaces contre les maladies liées à CD11c ?\nY a-t-il des effets secondaires aux traitements ciblant CD11c ?\nComment les traitements sont-ils adaptés aux niveaux de CD11c ?\nLes traitements sont-ils disponibles pour tous les patients ?",
"url": "https://questionsmedicales.fr/mesh/D039521?mesh_terms=Lymph+Node+Excision&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antigènes CD11c",
"description": "Quelles complications peuvent survenir avec CD11c élevé ?\nLes complications sont-elles réversibles ?\nComment gérer les complications liées à CD11c ?\nLes complications affectent-elles la qualité de vie ?\nY a-t-il des risques de complications à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D039521?mesh_terms=Lymph+Node+Excision&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antigènes CD11c",
"description": "Quels sont les facteurs de risque pour CD11c élevé ?\nL'âge influence-t-il les niveaux de CD11c ?\nLe mode de vie affecte-t-il les niveaux de CD11c ?\nLe stress est-il un facteur de risque pour CD11c ?\nLes infections antérieures influencent-elles CD11c ?",
"url": "https://questionsmedicales.fr/mesh/D039521?mesh_terms=Lymph+Node+Excision&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une expression anormale de CD11c ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'analyse se fait par cytométrie en flux pour évaluer l'expression de CD11c sur les cellules."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les antigènes CD11c ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests immunologiques comme l'immunofluorescence et la cytométrie en flux sont utilisés."
}
},
{
"@type": "Question",
"name": "Les antigènes CD11c sont-ils spécifiques à certaines maladies ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, leur expression est souvent associée à des maladies comme la leucémie ou le lupus."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance des antigènes CD11c dans le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils aident à identifier certains sous-types de cellules immunitaires et à diagnostiquer des pathologies."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer les niveaux de CD11c dans le sang ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les niveaux de CD11c peuvent être mesurés dans le sang par des techniques de laboratoire."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à une surexpression de CD11c ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des manifestations immunitaires comme des infections récurrentes."
}
},
{
"@type": "Question",
"name": "La présence de CD11c est-elle liée à des symptômes spécifiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surexpression peut être liée à des symptômes d'auto-immunité ou d'inflammation."
}
},
{
"@type": "Question",
"name": "Les antigènes CD11c sont-ils liés à des symptômes neurologiques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent un lien potentiel entre CD11c et des troubles neurologiques dans certaines conditions."
}
},
{
"@type": "Question",
"name": "Comment les symptômes varient-ils selon les niveaux de CD11c ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés peuvent entraîner des symptômes plus graves d'inflammation ou d'auto-immunité."
}
},
{
"@type": "Question",
"name": "Les symptômes d'une maladie liée à CD11c sont-ils réversibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela dépend de la maladie sous-jacente; certains symptômes peuvent être réversibles avec traitement."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les maladies liées à CD11c ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mesures préventives comme un mode de vie sain peuvent réduire les risques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins liés aux antigènes CD11c ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques ciblant les antigènes CD11c."
}
},
{
"@type": "Question",
"name": "Comment le dépistage précoce aide-t-il à prévenir les complications ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le dépistage précoce permet d'identifier les anomalies et d'initier un traitement rapide."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles CD11c ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée peut moduler la réponse immunitaire et l'expression de CD11c."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur CD11c ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut affecter la fonction immunitaire et l'expression de CD11c."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les antigènes CD11c ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies immunomodulatrices et des anticorps monoclonaux peuvent cibler CD11c."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces contre les maladies liées à CD11c ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent réduire l'inflammation et améliorer les symptômes associés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ciblant CD11c ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme des réactions allergiques ou des infections peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment les traitements sont-ils adaptés aux niveaux de CD11c ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements sont ajustés en fonction des niveaux de CD11c et de la gravité des symptômes."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils disponibles pour tous les patients ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'accès aux traitements peut varier selon les pays et les systèmes de santé."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec CD11c élevé ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des infections graves ou des maladies auto-immunes peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié, d'autres non."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à CD11c ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi médical régulier et des traitements adaptés aux symptômes."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement affecter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de complications à long terme ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des risques de complications chroniques existent, surtout en cas de maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour CD11c élevé ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux de maladies auto-immunes et des infections."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les niveaux de CD11c ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge peut influencer l'expression de CD11c et la réponse immunitaire globale."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il les niveaux de CD11c ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter les niveaux de CD11c."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque pour CD11c ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut augmenter l'expression de CD11c et affecter la santé immunitaire."
}
},
{
"@type": "Question",
"name": "Les infections antérieures influencent-elles CD11c ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des infections antérieures peuvent moduler l'expression de CD11c et la réponse immunitaire."
}
}
]
}
]
}
Jugulo-omohyoid lymph nodes (JOHLN) metastasis has proven to be associated with lateral lymph node metastasis (LLNM). This study aimed to reveal the clinical features and evaluate the predictive value...
A total of 550 patients pathologically diagnosed with PTC between October 2015 and January 2020, all of whom underwent thyroidectomy and lateral lymph node dissection, were included in this study....
Thyroiditis, tumor location, tumor size, extra-thyroidal extension, extra-nodal extension, central lymph node metastasis (CLNM), and LLMM were associated with JOHLN. Male, upper lobe tumor, multifocal...
JOLHN metastasis could be a clinically sensitive predictor of further LLM. A high-performance nomogram was established, which can provide an individual risk assessment of LNM and guide treatment decis...
Regional lymph node micrometastases from Merkel cell carcinoma (MCC) can be treated with completion lymph node dissection (CLND) and/or radiation therapy (RT). It is unclear how these options compare ...
This retrospective cohort study used data from years 2012-2019 of the National Cancer Database. Patients with MCC and clinically negative, but pathologically positive, lymph node metastases who receiv...
A total of 962 patients were included [median (interquartile range) age, 74 (67-80) years, 662 (68.8%) male patients, 926 (96.3%) white patients]. The majority (63%, n = 606) had a CLND only, while 18...
The usage of RT for nodal micrometastasis in MCC is increasing as compared with CLND. This strategy appears to be safe, with no significant difference in survival outcomes....
Rectal or anal canal adenocarcinoma with inguinal lymph node metastasis (ILNM) is rare and is associated with poor prognostic outcomes. This study aimed to elucidate the clinical significance of neoad...
This study enrolled 15 consecutive patients who underwent neoadjuvant therapy and curative resection for rectal or anal canal adenocarcinoma with clinically suspected ILNM between 2005 and 2019 at a s...
Out of the15 patients, 11 were treated with neoadjuvant chemoradiation, three with chemotherapy, and one with chemoradiation followed by chemotherapy. Fluorodeoxyglucose (FDG)-positron emission tomogr...
In patients with rectal or anal canal adenocarcinoma associated with clinical ILNM, radical resection with neoadjuvant therapy provides a good long-term survival....
Lateral pelvic node dissection (LPND) poses significant technical challenges. Despite the advent of robotic surgery, determining the optimal minimally invasive approach remains a topic of debate. This...
This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) 2020 and AMSTAR 2 (Assessing the Methodological Quality of Systematic Revie...
Six eligible studies involving 652 patients (316 and 336 in the R-LPND and L-LPND groups, respectively) were retrieved. The robotic approach demonstrated favourable outcomes compared with the laparosc...
In summary, the robotic approach is a safe and feasible alternative for Total Mesorectal Excision (TME) with LPND in advanced rectal cancer. Notably, it is associated with lower morbidity, particularl...
To determine the predictors of pelvic lymph-node metastasis in cases of squamous cell carcinoma (SCC) of penis....
Data was retrospectively collected from 267 cases of SCC penis that presented at our institute between 2009 and 2019. Univariate and multivariate logistic regression models were used to identify indep...
Pelvic Lymph-Node Metastasis (PLNM) was pathologically detected in 56 groins (29.2%). A cut-off of 0.25 was calculated for LNR based on ROC. LNR >0.25 (p = 0.003), ENE (p = 0.037), and LVI (p = 0.043)...
LNR >0.25, LVI and, ENE are independent predictors of PLNM. The discriminative ability of LNR was better than PLN. PLND could be avoided if no risk factors are present....
The objective of this study was to identify factors associated with lymph node yield (LNY) during surgeries for pulmonary sarcomatoid carcinoma (PSC) and to determine effects of lymph node density (LN...
The SEER Research Plus database was searched for data on patients with PSC from 1988 to 2018. Poisson regression was used of all patients with PSC to identify relevant factors associated with LNY. Uni...
There were 545 eligible patients in the study sample, 175 of which were LN-positive. These patients had significantly lower 5-year OS than those with no positive LNs ( P <0.001). Poisson regression an...
Patients with PSC with high LND experienced worse outcomes than those with low LND. Further risk stratification of patients with PSC may help to improve survival benefits based on prognostic indicator...
The aim of this study is to assess the impact of lymph node ratio (LNR) and number of positive lymph nodes (NPLN) on mortality and recurrence rates in patients with laryngeal squamous cell carcinoma....
We conducted a retrospective multicenter international study involving 24 Otorhinolaryngology-Head and Neck Surgery divisions. Disease-specific survival (DSS) and disease-free survival (DFS) were eval...
2507 patients met the inclusion criteria. DSS and DFS were significantly different in the groups of patients stratified according to LNR and NPLN. The 5-year DSS and DFS based on LNR and NPLN demonstr...
Our data demonstrate the potential prognostic value of NPLN and LNR in laryngeal squamous cell carcinoma....
The metastatic lymph node (LN) ratio (LNR) has shown to be an important prognostic factor in various gastrointestinal malignancies. Nevertheless, the prognostic significance of LNR in gallbladder carc...
From January 2007 to January 2018, 144 advanced GBC patients (T2-4 stages) who underwent curative surgery with at least 6 LNs retrieved were enrolled. Receiver operating characteristic (ROC) curve was...
The optimal cut-off point for LNR was 0.28 according to the ROC curve. LNR>0.28 was associated with higher rate of D2 LN dissection (P=0.004) and higher tumor stages (P<0.001). Extent of liver resecti...
LNR is correlated to advanced GBC prognosis and is a potential prognostic factor for advanced GBC with at least 6 LNs retrieved....
Axillary lymph node dissection is the standard surgical procedure for breast cancer patients with sentinel lymph node (SLN) positive. In clinical practice, axillary lymph node dissection may be an unn...
Lymph node status is vital for gastric cancer (GC) prognosis, but the conventional pN stage may be limited by variations in lymphadenectomy and stage migration. The N-Ratio, which assesses the ratio o...
To assess N-Ratios prognostic value in GC, particularly in patients with <25 resected lymph nodes....
Patients who underwent gastrectomy with curative intent for GC were retrospectively evaluated. The N-Ratio categories were determined using the ROC curve method, and the area under the curve (AUC) was...
A total of 561 GC patients were included in the study, 57% had pN+ status, and 17.5% had <25 resected lymph nodes. N-Ratio, with a mean of 0.12, predicted survival with 74% accuracy (AUC=0.74; 95%CI 0...
N-Ratio influenced survival in GC patients, especially in advanced lymph node disease (N-Ratio 3). Considering that N-Ratio does not impact pN0 cases, individualized prognosis assessment is essential ...